Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics Plc ADR (NQ: BCYC )

15.00 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 15.00
Bid (Size) 12.00 (1)
Ask (Size) 18.97 (2)
Prev. Close 15.00
Today's Range 15.00 - 15.00
52wk Range 14.95 - 62.08
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Analyst Ratings for Bicycle Therapeutics
Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings within the last quarter: 
Via Benzinga

Performance

YTD
-74.79%
-74.79%
1 Month
-36.97%
-36.97%
3 Month
-67.05%
-67.05%
6 Month
-72.53%
-72.53%
1 Year
-50.25%
-50.25%

More News

Read More
Expert Ratings for Bicycle Therapeutics
Via Benzinga
Recap: Bicycle Therapeutics Q1 Earnings
Via Benzinga
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Where Bicycle Therapeutics Stands With Analysts
Via Benzinga
Why Bicycle Therapeutics Stock Is Soaring Today
Via Benzinga
B. Riley Securities Downgrades Rating to Neutral for Bicycle Therapeutics, Lowers Price Target To $33
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Via Benzinga
Will Bicycle Therapeutics, With A 25% Gain Today, Take On Pfizer In Covid?
Via Investor's Business Daily
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics's Return On Capital Employed Overview
Via Benzinga
What 4 Analyst Ratings Have To Say About Bicycle Therapeutics
Via Benzinga
Bicycle Therapeutics: Q4 Earnings Insights
Via Benzinga
Bicycle Therapeutics to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team
From Bicycle Therapeutics plc
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022
Via Benzinga
Best Stocks Of 2021: Meme Stocks, Biotechs Highlight Broad Sector Strength
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.